Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106543465 | 10654346 | 5 | F | 20141012 | 20160922 | 20141216 | 20160927 | EXP | BR-ROCHE-1507350 | ROCHE | 71.61 | YR | F | Y | 53.00000 | KG | 20160927 | CN | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106543465 | 10654346 | 1 | PS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | 300 MG (2 DF) | 103976 | 300 | MG | SOLUTION FOR INJECTION | /month | ||||||
| 106543465 | 10654346 | 2 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | 103976 | 300 | MG | SOLUTION FOR INJECTION | /month | |||||||
| 106543465 | 10654346 | 3 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | 103976 | SOLUTION FOR INJECTION | |||||||||
| 106543465 | 10654346 | 4 | C | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 50/250 UG | 0 | 2 | DF | QD | |||||||
| 106543465 | 10654346 | 5 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | 2 SPRAYS (JETS), QD (MORNING) | 0 | 2.5 | MG | QD | |||||||
| 106543465 | 10654346 | 6 | C | MAREVAN | WARFARIN SODIUM | 1 | Oral | 3.75 MG, QD | U | 0 | 3.75 | MG | TABLET | QD | |||||
| 106543465 | 10654346 | 7 | C | MAREVAN | WARFARIN SODIUM | 1 | Oral | 2.5 MG, (1 TABLET AND HALF PER DAY) | U | 0 | 1.5 | DF | TABLET | QD | |||||
| 106543465 | 10654346 | 8 | C | LASIX | FUROSEMIDE | 1 | Unknown | 1 DF, QD | 0 | 1 | DF | TABLET | QD | ||||||
| 106543465 | 10654346 | 9 | C | PURAN | LEVOTHYROXINE SODIUM | 1 | Oral | 75 MG, QD | 0 | 75 | MG | TABLET | QD | ||||||
| 106543465 | 10654346 | 10 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MG, QD | 0 | 20 | MG | TABLET | QD | ||||||
| 106543465 | 10654346 | 11 | C | ONBRIZE | INDACATEROL MALEATE | 1 | Respiratory (inhalation) | FOR 4 MONTHS | 0 | 150 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 106543465 | 10654346 | 1 | Asthma |
| 106543465 | 10654346 | 4 | Asthma |
| 106543465 | 10654346 | 5 | Asthma |
| 106543465 | 10654346 | 6 | Coagulopathy |
| 106543465 | 10654346 | 8 | Diuretic therapy |
| 106543465 | 10654346 | 9 | Hypothyroidism |
| 106543465 | 10654346 | 10 | Abdominal discomfort |
| 106543465 | 10654346 | 11 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 106543465 | 10654346 | HO |
| 106543465 | 10654346 | OT |
| 106543465 | 10654346 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 106543465 | 10654346 | Apparent death | |
| 106543465 | 10654346 | Coagulation time shortened | |
| 106543465 | 10654346 | Immune system disorder | |
| 106543465 | 10654346 | Influenza | |
| 106543465 | 10654346 | Pulmonary embolism | |
| 106543465 | 10654346 | Thrombosis | |
| 106543465 | 10654346 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 106543465 | 10654346 | 1 | 20140617 | 0 | ||
| 106543465 | 10654346 | 3 | 20151018 | 0 | ||
| 106543465 | 10654346 | 5 | 2013 | 0 | ||
| 106543465 | 10654346 | 6 | 20141013 | 0 | ||
| 106543465 | 10654346 | 7 | 201510 | 0 | ||
| 106543465 | 10654346 | 8 | 20141013 | 0 |